We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




GE to Acquire Amersham for $9.5 Billion

By Biotechdaily staff writers
Posted on 14 Oct 2003
Immediately following the closing of its Instrumentarium acquisition, the General Electric Company (Waukesha, WI, USA) has agreed to buy Amersham plc (Little Chalfont, UK) for US$9.5 billion in stock.

Upon completion of the acquisition, Sir William Castell, CEO of Amersham, will become vice chairman and member of the board of General Electric. More...
He will also become CEO of the combined GE and Amersham medical businesses, to be called GE Healthcare Technologies, which will be based in the United Kingdom. Joseph Hogan, senior vice president of General Electric, will continue to lead the GE medical business.

Amersham Health (Little Chalfont, UK) is a global leader in diagnostic imaging agents, while Amersham Biosciences (Piscataway, NJ, USA) performs protein separations and develops instruments and software for research. Both segments are designed to advance GE's strategy of addressing high-growth segments of the healthcare industry. Amersham was formed in 1997 by the mergers of Amersham International (UK), Pharmacia Biotech (Sweden), and Nycomed (Norway). By adding these high-technology platforms to its diagnostic imaging, healthcare services, and information technology businesses, GE hopes to position the company to participate in new developments in molecular imaging and personalized medicine.

"GE and Amersham will be an exciting combination of talents, businesses, and technologies,” said Jeffrey R. Immelt, chairman and CEO of GE. "Amersham's diagnostic pharmaceutical and life sciences business will add new, high-growth platforms to GE Medical's diagnostic imaging, services, and healthcare information technology businesses.”




Related Links:
GE
Amersham

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.